ESR1 and prostate carcinoma: Both PvuII and XbaI can affect ESR1 transcription activity and possibly contribute to the elevated risk of prostate cancer [3], [6], [16], but the exact effects of ESR1 gene mutations on prostate epithelial cells are still debated despite the fact that estrogen is already used in treatming prostate cancer due to its growth-inhibitory effects [17].